ZNF331 and malignant colon neoplasm: We therefore conducted this analysis to evaluate the utility of ZNF331 promoter hypermethylation as a prognostic and/or predictive marker in stage III colon cancer patients enrolled in a large, well-annotated randomized phase III clinical trial.